Company / SG&A Expense
Insulet Corporation SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.2B
FY2025
5-year range
$466.0M / $1.2B
FY2021-FY2025
Trend
+27.0%
vs FY2024
Sector context
#40 of 152
Health Care
What the data says
At $1.2B, Insulet Corporation's sg&a expense ranks #113 of 152 in the Health Care sector. SG&A Expense has increased for 9 consecutive years, from $72M in FY2016 to $1.2B in FY2025.
Based on SEC 10-K filings.
$1.2B in FY2025 with a 5-year CAGR of +24.9%.
Increased from $735M to $1.2B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +25.6%
- 5-Year CAGR
- +24.9%
- 10-Year CAGR
- -
Sector benchmark
#113 of 152 in Health CareTop 74% of 152This company $1.2B Sector average $182.7B
▼
-99.4% below sector average
Key checks
Key Insights
- Insulet Corporation's sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +24.9%, indicating consistent growth.
- In FY2025, sg&a expense increased 27.0% year-over-year.
- Ranks #40 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2B | +27.0% |
| FY2024 | $917.2M | +24.8% |
| FY2023 | $734.8M | +25.0% |
| FY2022 | $587.8M | +26.1% |
| FY2021 | $466.0M | +21.4% |
| FY2020 | $384.0M | +28.9% |
| FY2019 | $298.0M | +20.2% |
| FY2018 | $248.0M | +192.8% |
| FY2017 | $84.7M | +18.3% |
| FY2016 | $71.6M | +18.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026